Salvias Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 05-07-2024
- Paid Up Capital ₹ 3.00 Cr
as on 05-07-2024
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.98 Cr
as on 05-07-2024
- Satisfied Charges ₹ 7.20 Cr
as on 05-07-2024
- Revenue 12.02%
(FY 2023)
- Profit 132.18%
(FY 2023)
- Ebitda 39.53%
(FY 2023)
- Net Worth 7.49%
(FY 2023)
- Total Assets 20.57%
(FY 2023)
About Salvias Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹11.98 Cr. The company has closed loans amounting to ₹7.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
Narayana Kanumuri, Venkata Meesal, Sivajiraju Nadimpalli, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24304AP2017PTC107243
- Company No.
107243
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Dec 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Salvias Pharma Private Limited offer?
Salvias Pharma Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Malaria Medicine, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Antiviral Drugs.
Who are the key members and board of directors at Salvias Pharma?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tirumala Sangam  | Director | 11-Jul-2020 | Current |
| Narayana Kanumuri | Director | 11-Jul-2020 | Current |
| Venkata Meesal | Director | 11-Jul-2020 | Current |
| Sivajiraju Nadimpalli | Director | 11-Jul-2020 | Current |
| Sreenivasa Devandla | Director | 14-Dec-2017 | Current |
| Srinivasa Angajala | Director | 14-Dec-2017 | Current |
Financial Performance of Salvias Pharma.
Salvias Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.02% increase. The company also saw a substantial improvement in profitability, with a 132.18% increase in profit. The company's net worth moved up by a moderate rise of 7.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Salvias Pharma?
In 2023, Salvias Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 25 Mar 2022 | ₹11.98 Cr | Open |
Others Creation Date: 03 Jan 2020 | ₹7.20 Cr | Satisfied |
How Many Employees Work at Salvias Pharma?
Salvias Pharma has a workforce of 50 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Salvias Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Salvias Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
